Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to test the safety and tolerability of intratumoral administration of MEM-288 in participants with NSCLC.
1. To determine the safety, tolerability, and maximum tolerated dose (MTD) of intratumoral administration of MEM-288 as a single agent.
1. To assess efficacy overall response rate in a variety of solid tumors, as well as disease control rate, progression free survival and duration of response.
2. To evaluate anti-tumor immune responses of intratumoral MEM-288 single agent by evaluating biopsy tissue of injected lesions and serial blood draws.
Ability to understand and provide informed consent.
Willingness and ability to comply with scheduled study visits and procedures.
Adult men or women over 18 years of age
ECOG performance status of 0 or 1.
Advanced/metastatic NSCLC patients only at Moffitt. cSCC, Merkel cell, melanoma, TNBC, pancreatic cancer, or head and neck cancer at other sites.
Per each tumor type, the specific initial standard of care therapies after which the patients with specific histologies must have progressed have been included. Patients will have been treated with at least one or more than one line of therapy prior to enrollment in the study.
Non-small cell lung cancer (NSCLC) - Must have progressed on standard therapy, including platinum-based chemotherapy and checkpoint inhibitor therapy (combined or sequential). Patients with tumors that have known actionable molecular alteration such in EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS must have progressed on standard directed molecular therapy, and platinum-based chemotherapy.
Progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status), except for patients with pancreatic cancer.
Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).
Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, must have been previously treated with an applicable tyrosine kinase inhibitor.
Tumor lesion which is deemed feasible for biopsy and injection under CT or ultrasound guidance by an interventional radiologist, and patient willing and able to provide tissue from biopsy of this lesion. Injected tumor should be > 1 cm3 in volume and should not encase or be inseparable from vital structures such as major nerves or blood vessels. For patients treated at the first dose level, the tumor for injection must be an accessible cutaneous, subcutaneous, or superficial lymph node lesion that is palpable.
Measurable disease, as defined per RECIST version 1.1.
Prior history of brain metastases are eligible, provided: Brain metastases have been treated. Asymptomatic from the brain metastases. Corticosteroids prescribed for the management of brain metastases have been discontinued at least 7 days before registration to study. Brain metastases are stable on pre-registration imaging. No evidence of leptomeningeal disease.
Life expectancy > 3 months.
Additional criteria apply
Serious uncontrolled medical disorder, psychiatric condition or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.
Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic), or significant traumatic injury, within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy are exceptions and patients can receive study treatment ≥1 week after these procedures.
History of clinically significant noninfectious interstitial pneumonitis (i.e., limiting activities of daily living or requiring therapeutic intervention), including clinically significant radiation pneumonitis.
Residual toxicity from prior anticancer therapy of grade 3 or greater (CTCAE v5.0), with the exception of alopecia.
Concurrent use of other anticancer approved or investigational agents.
Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months), such as: (a) unstable angina within 6 months prior to screening (b) myocardial infarction within 6 months prior to screening (c) history of documented congestive heart failure (New York Heart Association functional classification III-IV) (d) cardiac arrhythmias not controlled with medication
Active autoimmune disease requiring disease modifying therapy (except vitiligo, Grave's, or psoriasis not requiring systemic treatment).
Any form of active primary or secondary immunodeficiency.
Prior malignancy (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical/dysplasia endometrial, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period.
Active systemic infections requiring intravenous antibiotics.
Prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents (other than anti-PD-1/anti-PD-L1 monoclonal antibody).
Other criteria may apply
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub